Discover why 3 alarming autoimmune diseases are rising in kids, from genetics to environment, and what it means for their ...

The FDA has accepted Yuflyma as an interchangeable biosimilar to adalimumab for the treatment of multiple chronic inflammatory diseases, Celltrion USA announced in a press release.A high-concentration ...

Switzerland-based generic drug maker Sandoz said on Monday that it has filed an antitrust lawsuit against Amgen, Inc, (AMGN) ...

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing RulesCompany aims to accelerate access to much-needed biosimilar to reference ...

Sandoz sues Amgen in U.S. court over Enbrel patents, alleging efforts to block biosimilar Erelzi and delay competition in the ...

One of the worst complications of adult-onset Still's disease is macrophage activation syndrome (MAS), which can be fatal. In ...

Researchers have found in a new research that HLA-B27 genetic marker is linked to a higher risk of various arthropathies, including juvenile idiopathic arthritis (JIA), but its prognostic value ...

Biologic therapy was associated with more than seven times greater odds of reaching sustained remission compared with ...

Sandoz has filed an antitrust lawsuit in the United States against Amgen, for extending and entrenching the dominant market ...

Bio-Thera Solutions, the developer of the biosimilar, will continue to hold manufacturing rights in the US market.

Sandoz is seeking an injunction to prevent Amgen from using certain patent rights to block biosimilar competition and allow ...